COMPANY SPOTLIGHT - COMPANY SPOTLIGHT - Cephalon

PUB. DATE

March 2008

SOURCE

PharmaWatch: CNS;Mar2008, Vol. 7 Issue 3, p17

SOURCE TYPE

Market Research Report

DOC. TYPE

Article

ABSTRACT

The article presents a corporate profile for Cephalon Inc., an international biopharmaceutical company engaged in the discovery, development and marketing of products. Its business segments cover the core therapeutics areas which include central nervous system disorders, pain, oncology and addiction. The company's most significant product is Provigil tablets which comprised approximately 43% of Cephalon's total consolidated net sales for the year 2006.

ACCESSION #

31602404

Related Articles

The article discusses the services and operation of Cephalon Inc., a U.S. drug company. The firm is engaged in the development and marketing of drugs in four therapeutic areas including central nervous system (CNS) disorders, pain, cancer and addiction. The impressive performance of one of its...

Presents an overview of Cephalon Inc., a biopharmaceutical company engaged in developing and marketing drugs. Revenues generated in fiscal year ended December 2005; Principal diseases targeted, including central nervous system disorders, pain, cancer and addiction.

Provides a business analysis of Cephalon Inc., a biopharmaceutical company engaged in developing and marketing drugs, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths, including benefits derived from its strong revenue growth, and robust...

The article focuses on Cephalon Inc., a U.S.-based biopharmaceutical firm which manufactures products used in the treatment of sleep disorders, neurological and psychiatric disorders. The company recorder revenues of about $714.8 million in 2003 and has shown robust performance on almost all...

The article presents a corporate profile of biopharmaceutical company Pfizer Inc. The company develops, manufactures and markets branded prescription small molecule and biologic medicines, vaccines and consumer health products. It reorganized its businesses into two segments which are...

The article provides information related to drug development in the U.S. Targacept Inc. started its phase II trial of TC-2696 for the treatment of acute post-operative pain. Cephalon Inc. discovered from its new studies of pain drug Fentora that the onset of pain relief may be faster than the...

Presents an overview of Cephalon Inc., a biopharmaceutical company engaged in developing and marketing drugs. Company overview, including revenues generated in fiscal year ended December 2005, services provided, and principal drugs; Key facts, including contact information; Analysis of the...

The article reports on developments related to global biopharmaceutical industry including the worldwide license provided by LinXis BV to APO-T BV for the use Lx linker technology, creation of a subsidiary of Deinove to accelerate its antibiotic development program and the resubmission of a drug...